Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 13Lymphoid 2Other hematologic neoplasm 1Other 1Gastrointestinal 1

Conditions

Purpura 1Nausea 1Macroglossia 1Lymphadenopathy 1Immunoglobulin Light-chain Amyloidosis 1Hepatomegaly 1Gastrointestinal Hemorrhage 1Diarrhea 1Constipation 1

Interventions

Exercise 15Metformin 14Surveys and Questionnaires 12Radiotherapy 9Methods 7naloxegol 6Nutrition Assessment 6Counseling 6alvimopan 5Resistance Training 5Psychiatric Rehabilitation 5Exenatide 5Early Intervention, Educational 5Diet Therapy 5Diet 5Sugars 4Mindfulness-Based Stress Reduction 4Injections 4Fibroblast Growth Factor 7 4Educational Status 4Drug Therapy 4Vitamin D 3Therapeutics 3Standard of Care 3Liraglutide 3Interviews as Topic 3Fentanyl 3Cryotherapy 3Cognitive Behavioral Therapy 3Cisplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × isatuximab × Other × Clear all
NCT03499808 2025-09-09

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

SWOG Cancer Research Network

Phase 2 Completed
43 enrolled 23 charts
GastrointestinalOtherPlasma cell

Lymphadenopathy, Immunoglobulin Light-chain Amyloidosis, Constipation, Diarrhea, Gastrointestinal Hemorrhage, Hepatomegaly, Macroglossia, Nausea, Purpura

Data powered by HemOnc (CC BY 4.0) Colophon âš¡